CHICAGO, Illinois — A genetic change or variant in a gene called SCN2A is a known cause of infantile seizures, autism spectrum disorder and intellectual disability, as well as a wide range of other moderate-to-profound impairments in mobility, communication, eating and vision. The severity of these disorders can vary widely...
Latest News
South Bend, Indiana – Certain types of light have proven to be an effective, minimally invasive treatment for cancers located on or near the skin when combined with a light-activated drug. But deep-seated cancers, surrounded by tissue, blood and bone, have been beyond the reach of light’s therapeutic effects. To...
South Bend, Indiana – Researchers at the University of Notre Dame have developed a novel, automated device capable of diagnosing glioblastoma, a fast-growing and incurable brain cancer, in less than an hour. The average glioblastoma patient survives 12-18 months after diagnosis. The crux of the diagnostic is a biochip that...
South Bend, Indiana – What could cancer teach us about tuberculosis? That’s a question Meenal Datta has been chasing since she was a graduate student. Once the body’s immune system is infected with tuberculosis, it forms granulomas — tight clusters of white blood cells — in an attempt to wall...
Notre Dame’s famous “Touchdown Jesus” mural lit up for Rare Disease Day on Tuesday.
BASEL, Switzerland – Nouscom, a clinical-stage biotech company developing next-generation immunotherapies to treat cancer at all stages, from early cancer interception to late-stage metastatic disease, today announced that results from its Phase 1b/2 clinical trial of NOUS-209 in Lynch Syndrome (LS) carriers have been published in Nature Medicine (D’Alise et...
Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of cancer, especially colorectal and endometrial, to as high as 80% NOUS-209 is an off-the-shelf immunotherapy designed to harness the power of the immune system to recognize and eliminate cancer cells before tumors develop Final...
BASEL, Switzerland – Nouscom, a clinical-stage biotech company developing next-generation off-the-shelf and personalized neoantigen cancer immunotherapies, today announced the presentation of new clinical and translational data on its lead candidate NOUS-209 at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting. Following positive safety and immunogenicity data reported at...
FALLS CHURCH, Va. – This year, nearly 2 million Americans will be diagnosed with cancer. But one-quarter won’t fill their expensive prescriptions, and another 20% will ration their drugs due to cost – which can total $15,000 per month or more. But thanks to a partnership between NOVA ScriptsCentral and...
Mont Saint-Guibert and Brussels, Belgium – Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, and the Cliniques universitaires Saint-Luc today announce the successful treatment of four pediatric patients with Congenital Pseudarthrosis of the Tibia (CPT) using NVD003, an autologous therapy developed by Novadip for the reconstruction of...